Sosei Subsidiary Heptares, AstraZeneca Announce Agreement to Develop Novel Immuno-Oncology Treatments for Range of Cancers

Sosei Group Corporation SOLTF is pleased to announce that its wholly-owned subsidiary Heptares Therapeutics and AstraZeneca AZN have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds. AstraZeneca will focus on exploring HTL-1071 and any additional compounds across a range of cancers, including in combination with its existing portfolio of immunotherapies. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating A2A receptors, adenosine stops T-cells within See full press release